- Press Release Distribution

A Canadian success story: world-first to treat Fabry disease with gene therapy

A Canadian success story: world-first to treat Fabry disease with gene therapy
( (Thursday, Feb. 25, 2021, Toronto)--Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.

The Canadian research team was the first to use gene therapy in 2017 to treat patients with Fabry disease, a rare, chronic illness that can damage major organs and shorten lives. They report their findings today in the journal Nature Communications.

"Being one of the first people in the world to receive this treatment, and seeing how much better I felt afterward, it definitely gives me hope that this can help many other Fabry patients and potentially those with other single gene mutation disorders," says Ryan Deveau, one of the participating patients in Dartmouth, Nova Scotia. "Now that I don't have to get the replacement therapy every two weeks, I have more time to spend with my family."

Fabry patients currently must undergo enzyme therapy infusions every two weeks. Gene therapy would enable them to receive a single treatment that could prove to be more effective clinically since the modified blood stem cells continuously produce corrected versions of the defective enzyme.

"To date, we can say that the gene therapy has either partially or fully restored enzyme levels to a point where they are no longer considered deficient," says Dr. Aneal Khan, the Alberta Health Services medical geneticist and member of the Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, who is leading the experimental trial in Calgary.

"These results show that just one treatment of gene therapy was enough to benefit patients. Now we need to see whether this single dose can last for the long term."

Five men participated in the study and were treated at Alberta Health Services' Foothills Medical Centre in Calgary, Princess Margaret Cancer Centre, Toronto, and Nova Scotia Health's Queen Elizabeth II Health Sciences Centre in Halifax.

As a result of the gene therapy, all patients began producing the corrected version of the enzyme to near normal levels within one week. With these initial results, all five patients are approved by Health Canada to stop their intravenous enzyme therapy. So far, three patients have chosen to do so, and are stable.

"This really was a ground-breaking study, given current therapies are not cures," says Dr. Michael West, nephrologist and Nova Scotia Health co-investigator, with Dr. Stephen Couban, a hematologist. "This is the next step in moving toward a better therapy and hopefully a cure for this disease, which can really cause patients a lot of pain and suffering. It's promising that the participating patients are still seeing benefit from the treatment several years after the procedure was completed."

Patients were followed from January 2017 to February 2020 for this study, and ongoing follow-up will extend until February 2024.

Clinicians emphasize it will take many years of further testing before this experimental treatment becomes a clinically available standard of care.

"To actually see that this therapy was working in patients was humbling," says Dr. Jeffrey Medin, who pioneered the treatment while he was a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN). Dr. Medin is now the MACC Fund Professor at the Medical College of Wisconsin and Affiliate Scientist, UHN.

"After 20 years of working on this treatment, to see that patients could end up making their own enzyme, and that the treatment effect was sustained is satisfying. We are elated!"

Darren Bidulka, 52, was the first patient treated in the study on January 11, 2017, at Alberta Health Services' Foothills Medical Centre. He was diagnosed with Fabry disease in 2005, and was on enzyme therapy for years.

"I'm really happy that this worked," he says. "What an amazing result in an utterly fascinating experience. I consider this a great success.

"I can lead a more normal life now without scheduling enzyme therapy every two weeks. This research is also incredibly important for many patients all over the world, who will benefit from these findings."

In the study, researchers collected a quantity of a Fabry patient's own blood stem cells, then used a specially engineered virus to inject those cells with copies of the fully functional gene that is responsible for the enzyme. The modified stem cells were then transplanted back into each patient.

People with Fabry disease have a gene called GLA that does not function correctly. As a result, their bodies are unable to make the correct version of an enzyme that breaks down a fat. A buildup of that can lead to problems in the kidneys, heart and brain.

The treatment, which was approved by Health Canada for experimental purposes, was the first trial in Canada to use a lentivirus in gene therapy. In this case, the specially modified virus was created at Princess Margaret Cancer Centre, stripped of its disease-causing capability and augmented with a working copy of the gene that's responsible for the missing enzyme.

Lentiviruses are a family of viruses that can cause diseases like acquired immunodeficiency syndrome (AIDS), and are used world-wide in many clinical trials because of the ease with which they can enter and insert genetic material into cells. They are well understood by the research community, and easy to manufacture in large quantities, which was required for this study.

The trial focused on men because the gene for Fabry disease is on the X-chromosome, so it is inherited as an X-linked disorder. Men are therefore more severely affected than women, because each man carries only one X chromosome.

Men therefore present with more severe symptoms, such as burning in hands and feet, kidney failure, or gastrointestinal symptoms such as abdominal cramping, frequent bowel movements, diarrhea, nausea or vomiting. Untreated, men have an average lifespan of 58 years and women, 75 years.

An estimated one person in 40,000 to 60,000 has Fabry disease. There are more than 500 people in Canada known to have this illness, although exact numbers are not known due to the difficulty in identifying all those with the disease.

"Studies such as this can pave the way for additional clinical trials in Fabry disease and for many other metabolic disorders. It also shows that it is possible to coordinate such a complex study at multiple sites, even across international borders, as some analyses were done at the Medical College of Wisconsin," says Dr. Medin, who has been working on the project since he was at the National Institutes of Health in Bethesda, MD.


Competing Interests

UHN has a financial interest in a licensing agreement with AVROBIO, Inc., granting AVROBIO exclusive rights to manufacture and commercialize the gene therapy studied in this Phase 1 clinical trial.

Aneal Khan: AVROBIO: consulting fees, grants, revenue distribution agreement, speaker fees and travel support; University Health Network: revenue distribution agreement. Anthony Rupar: AVROBIO: service contract. Christiane Auray-Blais: AVROBIO: honoraria and service contract. Armand Keating: AVROBIO: consulting fees unrelated to this study. Michael L. West: Amicus Therapeutics: consulting fees, grants, speaker fees and travel support; Protalix: consulting fees, grants, speaker fees and travel support; Sanofi-Genzyme: consulting fees, grants, speaker fees and travel support; Takeda Pharmaceuticals: consulting fees, grants, speaker fees and travel support; and University Health Network: revenue distribution agreement. Jeffrey A. Medin: AVROBIO: scientific co-founder and shareholder; Rapa Therapeutics: scientific advisory board; Sanofi-Genzyme: honorarium, Shire: honorarium.

Support for this study provided by: Canadian Institutes of Health Research (CIHR), the Kidney Foundation of Canada and the MACC Fund, and AVROBIO, Inc. Juravinski Hospital, London Health Sciences Centre and Université de Sherbrooke provided critical laboratory support in stem and progenitor cell isolation, assay of enzymatic activity and metabolite levels, respectively.

About Princess Margaret Cancer Centre

Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. All are research hospitals affiliated with the University of Toronto. For more information:

About Alberta Health Services

Alberta Health Services is the provincial health authority responsible for planning and delivering health supports and services for more than four million adults and children living in Alberta. Its mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.

About Nova Scotia Health

Nova Scotia Health provides health services to Nova Scotians and a wide array of specialized services to Maritimers and Atlantic Canadians. Nova Scotia Health operates hospitals, health centres and community-based programs across the province. Our team of health professionals includes employees, doctors, researchers, learners and volunteers. We work in partnership with community groups, schools, governments, foundations and auxiliaries and community health boards.

[Attachments] See images for this press release:
A Canadian success story: world-first to treat Fabry disease with gene therapy


Chimpanzees and humans share overlapping territories

Chimpanzees and humans share overlapping territories
Chimpanzees and humans "overlap" in their use of forests and even villages, new research shows. Scientists used camera traps to track the movements of western chimpanzees - a critically endangered species - in Guinea-Bissau. Chimpanzees used areas away from villages and agriculture more intensively, but entered land used by humans to get fruit - especially when wild fruits were scarce. Researchers from the University of Exeter and Oxford Brookes University say the approach used in this study could help to inform a "coexistence strategy" for chimpanzees ...

Allergy season starts earlier each year due to climate change and pollen transport

Allergy season starts earlier each year due to climate change and pollen transport
Allergy sufferers are no strangers to problems with pollen. But now - due to climate change - the pollen season is lasting longer and starting earlier than ever before, meaning more days of itchy eyes and runny noses. Warmer temperatures cause flowers to bloom earlier, while higher CO2 levels cause more pollen to be produced. The effects of climate change on the pollen season have been studied at-length, and END ...

Study shows opioid use among US patients with knee osteoarthritis costs 14 billion dollars in societal costs

Although guidelines do not recommend use of opioids to manage pain for individuals with knee osteoarthritis, a recent study published early online in END ...

On the line: Watching nanoparticles get in shape

Liquid structures - liquid droplets that maintain a specific shape - are useful for a variety of applications, from food processing to cosmetics, medicine, and even petroleum extraction, but researchers have yet to tap into these exciting new materials' full potential because not much is known about how they form. Now, a research team led by Berkeley Lab has captured real-time high-resolution videos of liquid structures taking shape as nanoparticle surfactants (NPSs) - soap-like particles just billionths of a meter in size - jam tightly together, ...

A-maze-ing pheasants have two ways of navigating

A-maze-ing pheasants have two ways of navigating
Pheasants fall into two groups in terms of how they find their way around - and the different types prefer slightly different habitats, new research shows. University of Exeter scientists tested whether individual pheasants used landmarks (allocentric) or their own position (egocentric) to learn the way through a maze. The captive-bred pheasants were later released into the wild, and their choice of habitat was observed. All pheasants favoured woodland, but allocentric navigators spent more time out in the open, where their landmark-based style is more useful. "Humans tend to use both of these navigational tactics and quite frequently combine them, ...

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found. In a study posted online today by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses, are significantly ...

Fantastic voyage: Nanobodies could help CRISPR turn genes on and off

The genetic tool CRISPR has been likened to molecular scissors for its ability to snip out and replace genetic code within DNA. But CRISPR has a capability that could make it useful beyond genetic repairs. "CRISPR can precisely locate specific genes," says Lacramioara Bintu, an assistant professor of bioengineering at Stanford. "What we did was attach CRISPR to nanobodies to help it perform specific actions when it reached the right spot on DNA." Her lab recently used this combo technique to transform CRISPR from a gene-editing scissors into a nanoscale control agent that can toggle specific genes on and off, like a light switch, to start or stop the flow of some health-related protein inside a cell. "There are a lot of things you can't fix ...

Baby mice have a skill that humans want - and this microchip might help us learn it

Baby mice might be small, but they're tough, too. For their first seven days of life, they have the special ability to regenerate damaged heart tissue. Humans, on the other hand, aren't so lucky: any heart injuries we suffer could lead to permanent damage. But what if we could learn to repair our hearts, just like baby mice? A team of researchers led by UNSW Sydney have developed a microchip that can help scientists study the regenerative potential of mice heart cells. This microchip - which combines microengineering with biomedicine - could help pave the way for new regenerative heart medicine research. The study is featured on the cover ...

New discoveries on the containment of COVID-19 finds travel bans are of limited value

BROOKLYN, New York, Wednesday, February 24, 2021 - Travel bans have been key to efforts by many countries to control the spread of COVID-19. But new research aimed at providing a decision support system to Italian policy makers, recently published in the Journal of the Royal Society Interface, suggests that reducing individual activity (i.e., social distancing, closure of non-essential business, etc.) is far superior in controlling the dissemination of Sars-CoV-2, the virus that causes COVID-19. The research, which has implications for the United States and other countries, found that limiting personal mobility through travel restrictions and similar tactics is effective only in the first phases of the epidemic, and reduces in proportion to the ...

UM scientists achieve breakthrough in culturing corals and sea anemones cells

UM scientists achieve breakthrough in culturing corals and sea anemones cells
MIAMI--Researchers have perfected the recipe for keeping sea anemone and coral cells alive in a petri dish for up to 12 days. The new study, led by scientists at the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science, has important applications to study everything from evolutionary biology to human health. Cnidarians are emerging model organisms for cell and molecular biology research. Yet, successfully keeping their cells in a laboratory setting has proved challenging due to contamination from the many microorganisms that live within these marine organisms or because the whole tissue survive in a culture environment. UM cell ...


Crop rotations with beans and peas offer more sustainable and nutritious food production

Five research-backed steps to a pro-vaccination social media campaign

1 in 4 parents give youth sports low rankings for enforcement of COVID-19 guidelines

Doctors still reluctant to prescribe medical cannabis: McMaster

Influence of sea surface temperature in the Indian Ocean on air quality in the Yangtze River Delta region

Frog species with 6 sex chromosomes offer new clues on evolution of complex XY systems

Study reveals the 3D structure of human uterine endometrium and adenomyosis tissue

ETRI develops a haptic film activated by LEDs

Researchers' work will help the pipeline industry limit the destructive power of bubbles

E-cigarettes with a cigarette-like level of nicotine are effective in reducing smoking

Deep Learning model developed at UHN to maximize lifespan after liver transplant 

Convenience over reputation: Study looks at how older adults pick a doctor

Ocean bacteria release carbon into the atmosphere

Spotting cows from space

Scientists watch 2D puddles of electrons emerge in a 3D superconducting material

Research suggests SEC's increasing focus on terrorism may limit financial oversight

Plastic planet: Tracking pervasive microplastics across the globe

Gut epithelium muscles up against infection

Scientists discover three liquid phases in aerosol particles

New mechanism identified behind blindness in older adults

Common approach to diversity in higher education reflects preferences of white Americans

Study reveals cancer immunotherapy patients at most risk of life-threatening side effects

Study reveals crucial details on skin-related side effects of cancer immune therapies

Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates

Differences in B cell responses to coronaviruses and other pathogens in children and adults

Bottom-up is the way forward for nitrogen reduction at institutions

Road salts and other human sources are threatening world's freshwater supplies

Researchers engineer probiotic yeast to produce beta-carotene

Spanking may affect the brain development of a child

UConn researchers find bubbles speed up energy transfer

[] A Canadian success story: world-first to treat Fabry disease with gene therapy